erenumab
erenumab: sourced relationships with 1 company · 6 clinical trials tracked · 1 FDA decision.
erenumab evidence translation
What we can confirm
1 FDA record · 6 tracked trials
What it means
What to watch
Prepared research question
How could erenumab → AMGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AMGEN INC (AMGN) Reported 2018-05-17 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (6)
Migraine Medication Effects on Urinary Symptoms
Primary endpoint: changes in OAB symptoms
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Primary endpoint: Change in worst pain intensity for each drug sub-study
China HeadAche DIsorders RegiStry
Primary endpoint: Headache Days
A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Primary endpoint: Change in the Number of Days Experiencing Moderate-to-Severe Headaches
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Primary endpoint: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3
Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
Primary endpoint: Defense and Veterans Pain Rating Scale (DVPRS)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with erenumab?
erenumab has dated SEC/FDA relationship records for AMGEN INC.
How many clinical trials involve erenumab?
BioSniper tracks 6 clinical trials involving erenumab.
What is erenumab's latest FDA decision?
The most recent tracked FDA decision for erenumab is Approval for 1 INDICATIONS AND USAGE AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 ), dated May 17, 2018.